MiniMed Group, Inc. Common Stock (MMED) Stock: Price, Forecast & Analyst Target
MiniMed Group, Inc. Common Stock (MMED) — MoonshotScore 38/100 (Weak band), calculated Oct 5, 2026. Price $19.93 (+1.17%), as of the Oct 5, 2026 trading session; market cap $5.60B.
Educational signal · not a buy or sell recommendation · How to read this
MiniMed Group, Inc. Common Stock · MMED · NASDAQ · Healthcare · Medical - Equipment & Services
Research dated 2026-09-13: MiniMed designs and manufactures diabetes management devices—insulin pumps, continuous glucose monitors, infusion sets, and supporting software—for patients and healthcare providers. The company reached profitability for the first time this quarter after mounting losses in prior periods, but the path ahead turns on whether new product launches can sustain that improvement or whether near-term cash burn resumes.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · MiniMed Group, Inc. Common Stock (MMED)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet — and it’s docked well below the pillars; verify the gap before trusting the setup. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $843M (Q1 FY2026, quarter ended Jul 31, 2026)
- EPS beat 0 of 3
- Altman Z 3.84 · Piotroski F 3
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak |
The score was 38 in the stored Oct 4, 2026 snapshot and remains 38 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $19.93 | |
| Change on the day | +1.17% | |
| 52-week range | $10.65 – $24.43 | |
| Market capitalisation | $5.60B | |
| Shares traded on the day | 7.7M | |
| Beta (volatility vs the S&P 500) | -3.7 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Management outlook
Earlier today, we announced that MiniMed Flex received CE Mark approval well ahead of our calendar year end target, and we now expect to begin our European launch in November of this year.
Que Dallara · Statement from
We completed the 510(k) filing for Fit with FDA ahead of our four targets, and we now expect a full U.S. launch by summer next year.
Que Dallara · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations can change.
Read management statementsOther perspectives
Council score for MiniMed Group, Inc. Common Stock (MMED): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Jun 15, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Jun 15, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the MMED film — every key number, told as a short cinematic story
~2 min · open the film
What is MiniMed Group, Inc. Common Stock (MMED), and what does it report?
Short answer · as of
MiniMed's business model divides into pumps, which anchor the installed base and attract premium pricing, and consumables, which provide recurring revenue as patients replenish infusion sets and other supplies.
Research dated 2026-09-13.
MiniMed's business model divides into pumps, which anchor the installed base and attract premium pricing, and consumables, which provide recurring revenue as patients replenish infusion sets and other supplies. The company recently went public, making this the first reporting cycle under full financial scrutiny. Revenue divides cleanly between pumps and consumables, with consumables now providing the majority of sales and positioning the company to benefit from recurring-revenue predictability. Gross margins compress at the consumables end compared to pumps, but the overall margin on each sales dollar remains robust. Research and product development spending has remained steady at historically elevated levels, consuming a meaningful share of gross profit without the variation that might indicate retrenchment. The puzzle: despite this favorable business-model shift toward higher-volume, recurring consumables, annual net losses have widened while sales climbed, suggesting operating expenses or non-operating items are growing faster than the top line.
What do the latest results show for MiniMed Group, Inc. Common Stock (MMED)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $843M.
Research dated 2026-09-13.
The most recent quarter shows revenue climbing for a second consecutive period, with consumables shipments driving the gain. Operating income turned positive for the first time in this reporting cycle, improving from the extended sequence of operating losses in prior periods. The recovery is meaningful but thin: a modest sequential profit in operating terms contrasts sharply with a net loss in the prior quarter, indicating that non-operating items—interest, tax, or other items—account for a growing wedge between operating performance and bottom-line results. Cash generation has turned negative in the latest quarter despite revenue strength, a concerning reversal from the historical pattern of positive quarterly cash flows. This divergence between operating income recovery and cash-flow deterioration is the central tension investors must resolve: Are the losses in the prior periods purely a timing issue from the company's restructuring as a public entity, or do they signal something structural about the business's capital intensity?
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $843.00M Jul 31, 2026
- Latest quarter · R&D
- $115.00M Jul 31, 2026
- Latest quarter · SG&A
- $312.00M Jul 31, 2026
- Latest quarter · FMP standardized operating result
- $38.00M Jul 31, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | $843.00M | $115.00M | $312.00M | $38.00M |
| Apr 24, 2026 | $837.00M | $99.00M | $299.00M | $82.00M |
| Jan 31, 2026 | $790.00M | $114.00M | $309.00M | −$93.00M |
| Oct 31, 2025 | $752.00M | $111.00M | $318.00M | −$10.00M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $843.00M Sep 1, 2026
- Latest report · revenue estimate
- $826.80M Sep 1, 2026
- Latest report · revenue vs estimate
- Above estimate Sep 1, 2026
- Latest report · EPS vs estimate
- Below estimate Sep 1, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Sep 1, 2026 | $843.00M | $826.80M | $0.1200 | $0.1241 |
| Jun 3, 2026 | $837.00M | $828.61M | −$0.6800 | −$0.1491 |
| Apr 17, 2026 | $790.00M | $789.48M | −$0.1600 | $0.1702 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $843M | $0 | $0.00 (diluted) |
| Q4 FY2025 | $837M | -$183M | -$0.68 (diluted) |
| Q3 FY2025 | $790M | -$119M | -$0.42 (diluted) |
| Q2 FY2025 | $752M | -$27M | $0.00 (diluted) |
What are the financial strengths and risks for MiniMed Group, Inc. Common Stock (MMED)?
Short answer
Cash and short-term investments were $207.00M at the Jul 31, 2026 balance-sheet date. Operating cash flow was −$49.00M for the quarter ended Jul 31, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The balance sheet carries minimal debt, with the debt-to-equity ratio near zero, freeing the company from financial leverage strain. Current and quick ratios both exceed the safe zone, meaning working capital is not a near-term risk. Cash and short-term investments cover several quarters of the most recent quarterly operating burn, providing a runway for the company to reach sustainable profitability. The Altman Z-score sits in the stable zone, and the Piotroski quality screen returns a low reading, consistent with a company transitioning from losses to profitability. The principal risk is whether operating margins hold or deteriorate again, which would wipe out the cash advantage within a compressed timeframe. Second-order risk: a slowdown in consumables adoption rates, which would undermine the logic of the business-model shift toward recurring revenue.
Data-derived red flags
- Negative return on equity (-9.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$49.00M Jul 31, 2026
- Previous quarter · operating cash flow
- −$170.00M Apr 24, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jul 31, 2026 | −$49.00M | −$41.00M |
| Apr 24, 2026 | −$170.00M | −$56.00M |
| Jan 31, 2026 | $66.00M | −$53.00M |
| Oct 31, 2025 | $48.00M | −$61.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at MiniMed Group, Inc. Common Stock (MMED)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $3.44B · EPS 0.67 · 10 analysts.
Research dated 2026-09-13.
Watch for two regulatory and commercial milestones. MiniMed Flex, the next-generation insulin pump, received European regulatory approval before the company's original target and is scheduled to launch in November. Fit, a competing pump, cleared its FDA filing ahead of internal expectations and is slated to reach the U.S. market by summer of the following year. Management guided that Flex margins should improve from current levels as manufacturing scales. Analyst estimates for the following years project material revenue growth and improving earnings per share, contingent on new-product adoption. The key observation is not the regulatory outcome—those are settled—but rather the commercial adoption curve in the period following each launch. European payers have historically resisted novel-device pricing in this category, so Flex success hinges on whether physicians and patients drive adoption despite formulary constraints, or whether uptake falters.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Earlier today, we announced that MiniMed Flex received CE Mark approval well ahead of our calendar year end target, and we now expect to begin our European launch in November of this year.
Que Dallara ·
We completed the 510(k) filing for Fit with FDA ahead of our four targets, and we now expect a full U.S. launch by summer next year.
Que Dallara ·
MiniMed Flex received CE Mark well ahead of our target of the end of the calendar year, and we expect full commercial launch starting in November of this year.
Que Dallara ·
We expect EBITDA margins to improve from Q1 levels as we move throughout fiscal '27, with a larger portion of the improvement occurring in the second half of the year, similar to what we saw last year.
Chad Spooner ·
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does MiniMed Group, Inc. Common Stock compare with its peers?
Short answer
MiniMed Group, Inc. Common Stock's score ranks 3rd of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
MiniMed occupies a narrow position in medical technology: larger than a startup but smaller and more focused than diversified medtech incumbents. Its peer set includes other single-disease, high-gross-margin device makers, though few in diabetes are as newly public or carry as-recent losses. The company's ratios and analyst coverage reflect that positioning. Institutional investors have increased their ownership stake significantly since listing, a signal of growing confidence, but insider transactions tell a different story—holders have sold shares over the trailing period without offsetting purchases. The forward estimates from analyst teams assume revenue expansion and operating leverage improvements, and the analyst consensus leans bullish across the major investment banks. The credibility of that consensus rides on execution of the product launches and evidence that the company can grow into its high R&D spend rather than carry it indefinitely as a drain on profitability.
| Company | Price | Market value | Score |
|---|---|---|---|
| $23.34 Oct 5, 2026 | $3.77B | 84 5-pillar Oct 5, 2026 | |
| $36.21 Oct 5, 2026 | $4.63B | 76 5-pillar Oct 5, 2026 | |
| MiniMed Group, Inc. Common Stock (MMED) — this page | $19.93 | $5.60B | 38 |
| $21.09 Oct 5, 2026 | $95.2M | 37 5-pillar Oct 5, 2026 | |
| $29.67 Oct 5, 2026 | $6.62B | 33 5-pillar Oct 5, 2026 | |
| $18.95 Oct 5, 2026 | $846M | 29 5-pillar Oct 5, 2026 | |
| $6.58 Oct 5, 2026 | $329M | 27 5-pillar Oct 5, 2026 | |
| $10.05 Oct 5, 2026 | $175M | 17 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $16.00 – $29.00
- Consensus target
- $25.88
- Median target
- $27.50
- Revenue estimate
- $3.44B
- EPS estimate
- $0.67
Consensus record · Captured .
Measured against a quoted price of $19.93 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 31, 2026
- Transactions
- 5
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 0
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 14.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 12.1% Prior to period end Jun 30, 2026
- Reporting holders
- 105 Period end Jun 30, 2026
- Previous quarter · holders
- 60 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Massachusetts Financial Services Co /Ma/ | 8,334,738 |
| Millennium Management LLC | 3,060,615 |
| Citadel Advisors LLC | 2,865,703 |
| Longaeva Partners L.P. | 2,812,970 |
| Sessa Capital Im, L.P. | 2,000,000 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about MiniMed Group, Inc. Common Stock (MMED)?
What Investors Ask About MiniMed Group, Inc. Common Stock (MMED) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is MiniMed Flex and why does it matter?
Flex is the company's next-generation insulin pump that secured European regulatory approval early and will launch commercially in November. Because the installed pump base represents the anchor customer relationship, success with Flex upgrades should translate into higher consumables attach rates and recurring revenue from the user base.
How much of the company's revenue comes from consumables versus pumps?
Consumables now represent the larger segment of revenue, a shift that has occurred across the trailing years as the installed pump base generates ever-larger volumes of recurring supply orders. This mix shift toward consumables should theoretically improve predictability, though recent losses suggest other pressures remain.
Why are the company's net losses expanding when revenue is growing?
Three factors: operating expenses including research spending have remained at high levels, non-operating items such as interest or one-time charges have grown, and the company is absorbing costs associated with its recent transition to a publicly traded entity. The latest quarter suggests recovery is possible, but the trend prior to that indicated the losses were widening rather than narrowing.
Is MiniMed a solid investment based on its balance sheet?
The balance sheet is clean: minimal debt, adequate working capital, and cash reserves sufficient to cover months of current burn. However, balance sheet strength alone does not determine value if operating losses persist or if the promised new products fail to drive adoption. The real question is execution, not liquidity.
What is the MMED stock price today?
The last price recorded on this page for MiniMed Group, Inc. Common Stock (MMED) is $19.93, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MMED price target?
The analyst consensus price target for MiniMed Group, Inc. Common Stock (MMED) is $25.88 (range $16.00 to $29.00, median $27.50), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Que Dallara (Sep 1, 2026): Earlier today, we announced that MiniMed Flex received CE Mark approval well ahead of our calendar year end target, and we now expect to begin our European launch in November of this year. Que Dallara (Sep 1, 2026): We completed the 510(k) filing for Fit with FDA ahead of our four targets, and we now expect a full U.S. launch by summer next year. Que Dallara (Sep 1, 2026): MiniMed Flex received CE Mark well ahead of our target of the end of the calendar year, and we expect full commercial launch starting in November of this year. Chad Spooner (Sep 1, 2026): We expect EBITDA margins to improve from Q1 levels as we move throughout fiscal '27, with a larger portion of the improvement occurring in the second half of the year, similar to what we saw last year. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Northridge, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "18000 Devonshire Street, Northridge, CA, 91325, US". |
FMP — 67 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $19.93 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T18:40:07.000Z. | |
px.change | Change on the day | +1.17% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.60B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T18:40:07.000Z. Captured from FMP at 2026-10-05T18:40:08.653Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.23 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q1 FY2026 | $843M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 7.7M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | -3.7 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Que Thanh Dallara | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 8,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 4 fiscal years, FY2023 through FY2026: FY2023 revenue $2.25B, net result −$96.00M; FY2024 revenue $2.47B, net result −$112.00M; FY2025 revenue $2.71B, net result −$250.00M; FY2026 revenue $3.10B, net result −$331.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Pumps $546.00M · Consumables $956.00M · Product and Service, Other $46.00M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 56.9% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-07-31.revenue_k | Revenue — period end 2026-07-31 | $843.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.rd_k | R&D — period end 2026-07-31 | $115.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.sga_k | SG&A — period end 2026-07-31 | $312.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-31.operating_result_k | FMP standardized operating result — period end 2026-07-31 | $38.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.revenue_k | Revenue — period end 2026-04-24 | $837.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.rd_k | R&D — period end 2026-04-24 | $99.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.sga_k | SG&A — period end 2026-04-24 | $299.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-24.operating_result_k | FMP standardized operating result — period end 2026-04-24 | $82.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.revenue_k | Revenue — period end 2026-01-31 | $790.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.rd_k | R&D — period end 2026-01-31 | $114.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.sga_k | SG&A — period end 2026-01-31 | $309.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-01-31.operating_result_k | FMP standardized operating result — period end 2026-01-31 | −$93.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.revenue_k | Revenue — period end 2025-10-31 | $752.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.rd_k | R&D — period end 2025-10-31 | $111.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.sga_k | SG&A — period end 2025-10-31 | $318.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-10-31.operating_result_k | FMP standardized operating result — period end 2025-10-31 | −$10.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-09-01.revenue_actual | Revenue · reported — report date 2026-09-01 | $843.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-01.revenue_estimated | Revenue · estimate — report date 2026-09-01 | $826.80M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-01.eps_actual | EPS · reported — report date 2026-09-01 | $0.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-01.eps_estimated | EPS · estimate — report date 2026-09-01 | $0.1241 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.revenue_actual | Revenue · reported — report date 2026-06-03 | $837.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.revenue_estimated | Revenue · estimate — report date 2026-06-03 | $828.61M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.eps_actual | EPS · reported — report date 2026-06-03 | −$0.6800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-06-03.eps_estimated | EPS · estimate — report date 2026-06-03 | −$0.1491 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-17.revenue_actual | Revenue · reported — report date 2026-04-17 | $790.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-17.revenue_estimated | Revenue · estimate — report date 2026-04-17 | $789.48M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-17.eps_actual | EPS · reported — report date 2026-04-17 | −$0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-17.eps_estimated | EPS · estimate — report date 2026-04-17 | $0.1702 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $207.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$49.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-07-31. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $75.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $59.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 1.53× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-07-31.operating_cash_flow_m | Operating cash flow — period end 2026-07-31 | −$49.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-24.operating_cash_flow_m | Operating cash flow — period end 2026-04-24 | −$170.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-07-31.capex_m | Capital expenditure (reported) — period end 2026-07-31 | −$41.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-24.capex_m | Capital expenditure (reported) — period end 2026-04-24 | −$56.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-31.operating_cash_flow_m | Operating cash flow — period end 2026-01-31 | $66.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-01-31.capex_m | Capital expenditure (reported) — period end 2026-01-31 | −$53.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-31.operating_cash_flow_m | Operating cash flow — period end 2025-10-31 | $48.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-10-31.capex_m | Capital expenditure (reported) — period end 2025-10-31 | −$61.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $16.00 – $29.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $25.88 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $27.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 5 transactions · 0 purchases, 0 sales, 5 other transactions · 5 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jul 31, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 14.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 12.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 105 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 60 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Massachusetts Financial Services Co /Ma/ — shares in provider snapshot | 8,334,738 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Millennium Management LLC — shares in provider snapshot | 3,060,615 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Citadel Advisors LLC — shares in provider snapshot | 2,865,703 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Longaeva Partners L.P. — shares in provider snapshot | 2,812,970 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Sessa Capital Im, L.P. — shares in provider snapshot | 2,000,000 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 7 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 0 of 3 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-09 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.84 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $10.65 – $24.43 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -9.1% · ROA -7.0% · current ratio 1.81 · earnings yield -5.9% · free-cash-flow yield -5.7% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $3.44B · EPS 0.67 · 10 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-03 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2027 | $3.44B | UNRECORDED | Stored analyst estimates — Captured 2026-10-03 · Expired observation | |
earn.est_eps | EPS estimate, FY2027 | $0.67 | UNRECORDED | Stored analyst estimates — Captured 2026-10-03 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-09-01.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($843.00M) with the recorded estimate ($826.80M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-09-01.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1200) with the recorded estimate ($0.1241) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 27.05× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $207.00M at Jul 31, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-07-31. The inputs do not establish a single common source date for this ratio. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 38 of 100 · Weak · pillars 73 / 79 / 62 / 57 / 85 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 38 (stored snapshot Oct 4, 2026) → 38 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-07-31. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-07-31.revenue_k,fin.q_table.depth.2026-07-31.rd_k,fin.q_table.depth.2026-07-31.sga_k,fin.q_table.depth.2026-07-31.operating_result_k,fin.q_table.depth.2026-04-24.revenue_k,fin.q_table.depth.2026-04-24.rd_k,fin.q_table.depth.2026-04-24.sga_k,fin.q_table.depth.2026-04-24.operating_result_k,fin.q_table.depth.2026-01-31.revenue_k,fin.q_table.depth.2026-01-31.rd_k,fin.q_table.depth.2026-01-31.sga_k,fin.q_table.depth.2026-01-31.operating_result_k,fin.q_table.depth.2025-10-31.revenue_k,fin.q_table.depth.2025-10-31.rd_k,fin.q_table.depth.2025-10-31.sga_k,fin.q_table.depth.2025-10-31.operating_result_k. - Earnings-history note. Source series as of 2026-09-01. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-09-01.revenue_actual,earn.history.depth.2026-09-01.revenue_estimated,earn.history.depth.2026-09-01.revenue_actual.comparison,earn.history.depth.2026-09-01.eps_actual.comparison,earn.history.depth.2026-09-01.eps_actual,earn.history.depth.2026-09-01.eps_estimated,earn.history.depth.2026-06-03.revenue_actual,earn.history.depth.2026-06-03.revenue_estimated,earn.history.depth.2026-06-03.eps_actual,earn.history.depth.2026-06-03.eps_estimated,earn.history.depth.2026-04-17.revenue_actual,earn.history.depth.2026-04-17.revenue_estimated,earn.history.depth.2026-04-17.eps_actual,earn.history.depth.2026-04-17.eps_estimated. - Cash-flow note. Source series as of 2026-07-31. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-07-31.operating_cash_flow_m,fin.opcf.depth.2026-04-24.operating_cash_flow_m,fin.opcf.depth.2026-07-31.capex_m,fin.opcf.depth.2026-04-24.capex_m,fin.opcf.depth.2026-01-31.operating_cash_flow_m,fin.opcf.depth.2026-01-31.capex_m,fin.opcf.depth.2025-10-31.operating_cash_flow_m,fin.opcf.depth.2025-10-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 5 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 4 entries
| 2026-04-24 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Revenue by segment | Pumps: $546.00M; Consumables: $956.00M; Product and Service, Other: $46.00M | 2026-04-24 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Trailing twelve-month ratio set | Quick ratio: 1.36; Current ratio: 1.81; Debt to equity: 0.02; Net margin: -10.2%; Gross margin: 53.8%; Operating margin: 0.5%; Return on assets: -7%; Return on equity: -9.1% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Operating cash flow by quarter (USD millions) | Captured record · 5 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $59.00M; Liquidity basis: cash and short-term investments; Total liabilities: $1.10B; Cash and short-term investments: $207.00M; Cash and investments: $282.00M; Long-term investments: $75.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Distress and quality screens | Altman Z-score: 4.27; Piotroski F-score: 3 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-09-01 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Analyst actions, most recent per firm | Captured record · 8 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-09-03 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Institutional ownership (13F) | Holders: 105; Quarter: 2026-06-30; Ownership: 13.3%; Holders previous quarter: 60; Ownership previous quarter: 12.7 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Insider transactions, last 180 days | Net shares: -71,333; Window days: 180; Price low: $16.31; Clustered days: 2026-07-31; Price high: $18.15; Buy transactions: 0; Distinct insiders: 5; Sell transactions: 0; Other transactions: 6; Total transactions: 6; Other transaction types: F-InKind: 6; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-07-31 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
Data provided for informational purposes only.